Ahmad Niazi a month ago Dr
Each has its own evidence base and safety boundary
nearly all efficacy evidence comes from animal or in vitro studies Fewer than 10 small human studies exist, none tracking use beyond about 12 weeks, so long-term safety (including cancer or fertility risk) is unknown Currently sits in a regulatory gray zone, complicating legitimate sourcing and quality assurance Side Effects: Most commonly reported issues are mild and short-lived: injection site soreness or reactions, occasional nausea, headache, and mild dizziness, typically resolving within hours to days
licensed UK options include orlistat, semaglutide (Wegovy, TA875), and liraglutide (Saxenda, TA664), all with established safety profiles
03 Review at week 8 Compare the current data with the baseline
The data were processed via Biacore T200 Evaluation Software v3.2 (Cytiva) and 1:1 binding model analysis